OUR PIPELINE

Dione is developing novel, direct acting, small molecule therapies against drug-resistant ’superbug’ and hard to treat infections with a focus on public health priority pathogens responsible for the most urgent, currently untreatable global health threats. Our portfolio targets Mycobacterium tuberculosis (MTB), Nontuberculous Mycobacteria (NTM), and Gram-negative (GN) bacteria, pathogens for which treatments are no longer effective due to the alarming spread resistance or are not available.